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A B S T R A C T
Background: The World Health Organization (WHO) recommends a 2-dose HPV vaccine schedule for girls aged
9–14 years. As randomised controlled trials assessing the immunogenicity and efficacy of a 1-dose schedule are
ongoing, we interviewed immunisation programme managers and advisors in low and middle-income countries
(LMIC) about a hypothetical, future reduction in the HPV vaccine schedule.
Methods: We conducted semi-structured interviews with LMIC immunisation programme managers and national
immunisation technical advisory group members (key informants; KIs) in 2017, recruited for their knowledge/
experience in national HPV vaccine policy and provision. Data were analysed thematically.
Results: We conducted 30 interviews with KIs from 18 countries. Perceived advantages of a 1-dose schedule
included reduced logistical and financial resources needed for vaccine delivery, fewer cold chain requirements
and easier integration into routine immunisation services. Perceived challenges included health worker hesi-
tancy, resources needed to re-mobilise communities and re-train health workers, potential misrepresentation of
schedule changes by anti-vaccine groups or the media. Half of interviewees suggested a WHO recommendation
would be necessary prior to policy change.
Conclusions: We found wide-ranging support among LMIC immunisation managers and advisors for a 1-dose
vaccine schedule if research demonstrated immunological and clinical evidence of efficacy, and WHO provided a
formal recommendation.
1. Background
Invasive cervical cancer (ICC), caused by persistent infection with
human papillomavirus (HPV), is a major public health problem, espe-
cially in low-income countries [1–3]. In countries where effective cer-
vical screening programmes are not in place or are only available on a
limited scale, women frequently present late with the disease, leading
to high morbidity and mortality [3,4]. However, there are now three
licensed prophylactic HPV vaccines, a bivalent, a quadrivalent and a
nonavalent vaccine, that can prevent between 70% and 90% of cervical
cancer cases by protecting against persistent infection with HPV vac-
cine genotypes, a necessary pre-requisite for the development of cer-
vical cancer and related cervical lesions [5].
In 2014, the Strategic Advisory Group of Experts on Immunisation
(SAGE) revised recommendations for the bivalent and quadrivalent
HPV vaccines from a schedule of three doses to two doses at an interval
of at least 6 months for girls aged 9–14 years old [6], based on evidence
of non-inferior immunogenicity [7–10]. Girls aged 15 years or older
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and HIV seropositive girls should receive three doses as per original
dosage recommendations [6].
By the end of 2016, Gavi, The Vaccine Alliance, had supported 23
low and middle-income countries (LMIC) to conduct HPV vaccine de-
monstration programmes. Although an increasing number of LMIC have
applied for Gavi support and been approved for national scale-up in
recent years, the sustained financial commitment required for vaccine
delivery is a key factor in some governments’ hesitancy to initiate na-
tional HPV vaccine programmes [11]. This is especially true for coun-
tries that are becoming ineligible for financial support from Gavi. These
countries must increase their co-financing commitments over time until
they are responsible for purchasing the vaccine at the full Gavi price
(currently US$4.50 per dose) [12].
There is some evidence that a single dose of HPV vaccine may elicit
a protective immune response. A combined, post-hoc analysis of 7466
women aged 18–25 years enrolled in two trials in Costa Rica and the
USA suggested equivalent efficacy of one, two and three doses of the
bivalent vaccine against vaccine-type persistent infection over a median
follow-up of 7 years [13–15]. A study in India among 17,729 girls aged
10–18 years participating in a clinical trial that was suspended because
of events unrelated to the study reported uniformly low frequencies of
cumulative incident HPV16 and 18 infections over 7 years post-vacci-
nation in all the vaccine dose groups and high vaccine efficacy in
preventing persistent HPV 16/18 infections, regardless of the number of
doses received [16,17]. A recent systematic review of evidence from
post-licensure observational studies reported highest effectiveness with
three HPV vaccine doses but almost half of the studies found some
evidence of effectiveness with one dose [18]. There are several rando-
mised controlled trials underway to investigate the efficacy and/or
immunogenicity of a single dose HPV vaccine compared to re-
commended schedules in Costa Rica [clinicaltrials.gov ID:
NCT03180034], Tanzania [clinicaltrials.gov ID: NCT02834637] and
The Gambia [19].
As scientific evidence accrues on a single dose schedule [18,20,21],
it is important to understand the potential policy implications of
changing schedules. We approached national immunisation programme
stakeholders in LMIC to 1) identify the motivators for and barriers to
changing the existing HPV vaccine schedule and what further in-
formation might be needed to inform a policy change to a one dose
schedule in their countries in future; 2) explore potential implications
of a further schedule change on the choice of delivery strategy and the
perceived cost and sustainability of the HPV vaccine programme; and 3)
collate experience and general attitudes towards off-label vaccine use
(defined as outside of manufacturers’ recommendations).
2. Methods
2.1. Country and participant selection
A total of 27 LMIC (World Bank 2016 classifications) with some
experience of HPV vaccine delivery through a demonstration project,
pilot or national programme were mapped and between one and three
key informants (KIs) per country were approached for interview. Due to
study timelines, a purposive selection of countries was made; countries
were prioritised in the first instance if they (i) supported a National
Immunisation Technical Advisory Group (NITAG) or equivalent group
which critically assesses evidence to inform government policy on
vaccinations and/or (ii) had existing links with the study team. The
final selection of countries included in the study was based on whether
the Key Informants (KI) consented to be interviewed.
KIs considered for inclusion comprised (i) members of the NITAG,
(ii) Expanded Programme on Immunisation (EPI) managers and/or HPV
focal points within the EPI programme, or (iii) EPI country partners
and/or international bodies (e.g. WHO country office, Unicef).
2.2. Interview procedures
After written informed consent was obtained, interviews were
conducted by phone using a semi-structured interview topic guide
(Supplementary Table 1). Interviews were recorded with written in-
formed consent. If KIs did not consent to be recorded, notes were
written up directly after the interview. Due to difficulties in arranging a
time for phone interviews, two interviewees responded to interview
questions by email.
2.3. Data management and synthesis
Data from interview transcripts were extracted onto an Excel matrix
by the interviewer and independently verified by a second team
member. The interview transcripts and recordings were stored on se-
cure servers only accessible by the study team. Qualitative information
was synthesized according to themes linked to each of the three ob-
jectives. The anonymity of interviewees was maintained for data sto-
rage purposes. However, all but one participant indicated their consent
for their job title and country of interview to be used in reports of re-
sults and other dissemination materials (referred to as ‘Country Z’).
Ethical approval for this study was granted by the London School of
Hygiene and Tropical Medicine Research Ethics Committee.
3. Results
Thirty stakeholders from 18 countries provided written informed
consent for interview between August and December 2017; more than
one interview was conducted in 61% of countries. Interviews were
conducted with nine EPI managers, 10 NITAG members, five WHO/
national immunisation managers and six other individuals (Table 1).
3.1. Perceived advantages of a 1 dose HPV vaccine schedule
All of the 30 KIs interviewed had a good comprehension of the
vaccine's effectiveness; 27 KIs (90%) representing all 18 countries
thought that a future, hypothetical schedule change to a single dose
HPV vaccine schedule would be supported by key stakeholders within
their country. Three KIs did not respond to the question directly. KIs
cited a range of potential advantages to a single dose HPV vaccine
schedule, 15 KIs anticipated a reduction in the financial resources
needed for vaccine delivery (Table 2).
The relative logistical ease of a one dose schedule, which would not
require girls to be traced for their second dose, was also a common
theme:
“[A one dose schedule] will be less work for nurses.. it's less time vac-
cinating.. so they have more time doing other activities in the clinics….
We have a problem with logistics and transportation in the country.” KI,
Solomon Islands.
3.2. Perceived barriers to a 1 dose HPV vaccine schedule
KIs from the same country were not always in agreement in their
perception of potential barriers to the introduction of a single dose
schedule. Fourteen KIs from 13 countries did not anticipate any barriers
to the hypothetical introduction of a one dose HPV vaccine schedule in
their country. Eight KIs from 6 countries cited concerns around gaining
community or individual acceptance of a single dose schedule in place
of two/three doses. KIs referred to the potential for individuals or
communities to question whether one dose would be sufficient to pro-
vide adequate protection, given the mobilisation and communication to
date on the importance of receiving two or three doses (Table 3).
In Kenya, there was concern that a further schedule change to one
dose soon after the schedule was reduced from three to two doses, could
be perceived by communities as a lack of sufficient evidence about
K.E. Gallagher et al. Papillomavirus Research 6 (2018) 33–40
34
Ta
bl
e1
Su
mm
ary
of
th
ep
art
ici
pa
tin
gc
ou
nt
rie
s,
HP
V
va
cc
ine
ex
pe
rie
nc
ea
nd
ke
yi
nfo
rm
an
ts.
Re
gio
n
Co
un
try
Ga
vi
eli
gib
ili
ty
sta
tu
sa
Na
tio
na
lP
ro
gr
am
m
eS
ta
tu
sb
HP
V
va
cc
in
e
ex
pe
rie
nc
e
St
ak
eh
ol
de
rs
in
te
rv
iew
ed
Af
ric
a
Et
hio
pia
Eli
gib
le
So
on
to
int
ro
du
ce
(G
av
ia
pp
lic
ati
on
su
cc
ess
ful
,
pr
oje
cte
di
nt
ro
du
cti
on
20
18
)
Ga
vi
de
mo
20
15
-17
1.
W
HO
Ro
ut
ine
Im
mu
niz
ati
on
Offi
ce
r
2.
Na
tio
na
lI
mm
un
isa
tio
nP
ro
gr
am
me
Offi
ce
r
3.
Na
tio
na
lI
mm
un
isa
tio
np
ro
gr
am
me
Co
or
din
ato
r
Ke
ny
a
Eli
gib
le
So
on
to
int
ro
du
ce
(G
av
ia
pp
lic
ati
on
su
cc
ess
ful
,
pr
oje
cte
di
nt
ro
du
cti
on
20
19
)
GA
P
de
mo
20
11
;
1.
Ec
on
om
ist
/P
oli
cy
Ad
vis
or
for
th
eD
ep
art
me
nt
of
Po
lic
y,
Pla
nn
ing
,a
nd
He
alt
h
Ca
re
Fin
an
cin
g
Ga
vi
de
mo
20
13
-17
2.
Na
tio
na
lI
mm
un
iza
tio
nP
ro
gr
am
me
Offi
ce
r
Le
so
th
o
Eli
gib
le
Int
ro
du
ce
d2
01
2-1
6(
pa
us
ed
)
GA
P
de
mo
(s)
20
09
–2
01
1;
1.
W
HO
Im
mu
niz
ati
on
Offi
ce
rf
or
Le
so
th
o
Na
tio
na
l2
01
2–
20
16
Co
un
try
‘Z’
Eli
gib
le
Un
kn
ow
n
Ga
vi
de
mo
20
14
-15
1.
NI
TA
G
Me
mb
er
Ni
ge
ria
Eli
gib
le
Un
kn
ow
n
No
ne
1.
NI
TA
G
me
mb
er
2.
NI
TA
G
me
mb
er
Se
ne
ga
l
Eli
gib
le
So
on
to
int
ro
du
ce
(G
av
ia
pp
lic
ati
on
su
cc
ess
ful
,
pr
oje
cte
di
nt
ro
du
cti
on
20
18
)
Ga
vi
de
mo
20
15
-17
1.
EP
Im
an
ag
er,
co
or
din
ato
ro
fn
ati
on
al
im
mu
niz
ati
on
pr
og
ram
me
Ug
an
da
Eli
gib
le
Int
ro
du
ce
d2
01
5
De
mo
(s)
20
08
-14
1.
EP
IT
ea
m
Le
ad
er
Na
tl.
20
15
-
2.
EP
IH
PV
Fo
ca
lP
ers
on
Za
mb
ia
Eli
gib
le
So
on
to
int
ro
du
ce
(G
av
ia
pp
lic
ati
on
su
cc
ess
ful
;
pr
oje
cte
di
nt
ro
du
cti
on
20
19
)
GA
P
de
mo
20
13
-14
1.
Na
tio
na
lE
PI
Ma
na
ge
r
Zim
ba
bw
e
Eli
gib
le
So
on
to
int
ro
du
ce
(G
av
ia
pp
lic
ati
on
su
cc
ess
ful
,
pr
oje
cte
di
nt
ro
du
cti
on
20
18
)
Ga
vi
de
mo
20
15
-17
1.
Di
rec
tor
of
Ep
ide
mi
olo
gy
an
dD
ise
as
eC
on
tro
la
nd
Zim
ba
bw
eN
IT
AG
Ch
air
pe
rso
n
2.
EP
IM
an
ag
er
So
ut
hE
as
tA
sia
La
oP
DR
Eli
gib
le
So
on
to
int
ro
du
ce
(G
av
ia
pp
lic
ati
on
su
cc
ess
ful
;
pr
oje
cte
di
nt
ro
du
cti
on
20
19
)
Ga
vi
de
mo
20
13
-15
1.
Na
tio
na
li
mm
un
isa
tio
n
Pr
og
ram
me
Ma
na
ge
r
2.
NI
TA
G
me
mb
er
Ne
pa
l
Eli
gib
le
Un
kn
ow
n
De
mo
20
08
–2
01
5
1.
Te
ch
nic
al
ad
vis
or
to
NI
TA
G
2.
Va
cc
ine
Offi
ce
rf
or
W
HO
Ne
pa
lO
ffi
ce
So
lom
on
Isl
an
ds
Eli
gib
le
So
on
to
int
ro
du
ce
(G
av
ia
pp
lic
ati
on
su
cc
ess
ful
;
pr
oje
cte
di
nt
ro
du
cti
on
20
19
)
Ga
vi
de
mo
s2
01
5-1
7
1.
EP
IP
ro
gr
am
me
Offi
ce
r
La
tin
Am
eri
ca
Ar
ge
nt
ina
c
Ine
lig
ibl
e
Int
ro
du
ce
d2
01
1
Na
tl:
20
11
-
1.
Di
rec
tor
of
Pr
ev
en
tab
le
Di
sea
ses
(M
oH
)
Bo
liv
ia
Ac
ce
ler
ate
dt
ran
sit
ion
ph
as
ed
Int
ro
du
ce
d2
01
7
De
mo
s2
00
9–
20
11
1.
PA
HO
/W
HO
Bo
liv
ia
EP
IC
on
su
lta
nt
Na
tl.
:2
01
7-
2.
Pr
esi
de
nt
of
NI
TA
G
Br
az
il
Ine
lig
ibl
e
Int
ro
du
ce
d2
01
4
De
mo
s2
01
0-1
2
1.
Co
or
din
ato
ro
fN
ati
on
al
Im
mu
niz
ati
on
Pr
og
ram
at
Mo
H,
NI
TA
G
me
mb
er
Na
tl.
20
14
-
Co
lom
bia
Ine
lig
ibl
e
Int
ro
du
ce
d2
01
2
Na
tl.
20
12
-
1.
NI
TA
G
an
dE
PI
Na
tio
na
lC
oo
rd
ina
tor
2.
Ot
he
r
Pe
ru
Ine
lig
ibl
e
Int
ro
du
ce
d2
01
1
De
mo
s2
00
7–
20
10
1.
Fo
rm
er
Mi
nis
ter
of
He
alt
h;
De
an
of
th
eP
ub
lic
He
alt
hF
ac
ult
ya
tt
he
Ca
ye
tan
oH
ere
dia
in
Pe
ru
Na
tl.
20
11
-
2.
NI
TA
G
Pr
esi
de
nt
Ea
ste
rn
Eu
ro
pe
Mo
ldo
va
Fu
lly
sel
f-fi
na
nc
ing
Un
kn
ow
n
GA
P
De
mo
20
10
-11
1.
He
ad
of
Ep
ide
mi
olo
gy
De
pa
rtm
en
to
fp
rev
en
tab
le
dis
ea
ses
th
ro
ug
hv
ac
cin
ati
on
wi
th
in
th
e
Na
tio
na
lC
en
tre
for
Pu
bli
cH
ea
lth
an
dN
IT
AG
me
mb
er
2.
NI
TA
G
Se
cre
tar
y
GA
P:
Ga
rd
as
il
Ac
ce
ss
Pr
og
ram
a
Ga
vi-
eli
gib
le:
3-y
ea
ra
ve
rag
eg
ro
ss
na
tio
na
li
nc
om
ep
er
ca
pit
a<
15
80
US
D
[1
2]
b
Th
es
tat
us
of
th
ec
ou
nt
ry
'sp
lan
sf
or
na
tio
na
lIn
tro
du
cti
on
of
HP
V
va
cc
ine
wa
si
nfo
rm
ed
by
inv
est
iga
tor
'sp
rev
iou
sc
on
tac
tw
ith
th
ec
ou
nt
ry
rep
res
en
tat
ive
sa
nd
Ga
vi'
sf
or
ec
as
tin
go
fs
uc
ce
ssf
ul
ap
pli
ca
tio
ns
at
th
et
im
e
th
is
stu
dy
wa
sb
ein
gc
on
du
cte
d.
‘So
on
to
int
ro
du
ce
’m
ea
nt
an
ap
pli
ca
tio
n
for
HP
V
va
cc
ine
su
pp
or
th
ad
be
en
pr
ep
are
d
by
co
un
try
rep
res
en
tat
ive
s(
an
d
ma
yh
av
eb
ee
n
su
bm
itt
ed
for
Ga
vi'
sc
on
sid
era
tio
n
or
ad
ate
for
su
bm
iss
ion
wa
sp
lan
ne
d)
.
c
Na
tio
na
lp
ro
gr
am
me
wa
sm
od
ifi
ed
in
20
17
to
inc
lud
ed
eli
ve
ry
to
bo
ys
an
dc
atc
h
up
va
cc
ina
tio
nt
o2
6y
ea
rs
of
ag
ef
or
pe
op
le
liv
ing
wi
th
HI
V.
d
Ga
vi
su
pp
or
tw
as
pr
ov
ide
df
or
th
efi
rst
ye
ar
of
th
en
ati
on
al
pr
og
ram
me
on
ly.
K.E. Gallagher et al. Papillomavirus Research 6 (2018) 33–40
35
which schedule is effective:
"It does raise concerns of very fast changes. i.e. it implies that compre-
hensive research was not really done at the outset and we are more on a
trial and error phase which many would not be comfortable with." KI,
Kenya.
Seven KIs from six countries cited potential acceptability issues
among HCWs as a potential barrier to a one dose HPV vaccine pro-
gramme, given that their training to date has specified two/three doses.
Five KIs stated that sourcing the resources needed for the retraining of
HCWs and remobilisation of the community would be a challenge if no
extra support was provided (Kenya, Ethiopia, Bolivia, Uganda, Country
Z). One KI explained that a formal recommendation from the WHO
would be useful to dispel any resistance propagated by anti-vaccine
groups. KIs from three countries mentioned the potential for informa-
tion around a further schedule change to be used negatively by girls
who had already been vaccinated and who were affected by adverse
events following immunisation or by anti-vaccine groups, or by the
media (Colombia, Peru, Kenya):
“I think [a one dose schedule] could be very good for the ones who are
not vaccinated yet, but … the ones who are saying that they suffered
adverse effects from the vaccine.. they could say “you gave us more doses
than we needed and that is why we got ill”.” KI, Colombia
“I always fear the anti-vaccine groups for example, if in some years
ahead someone who received only one dose developed cancer” KI, Peru
Another disadvantage cited by one KI (Ethiopia) included that a
single visit would impact the frequency of contact between the HCW
and the adolescent, thereby decreasing the opportunity for the provi-
sion of sexual and reproductive health (SRH) services for adolescents.
3.3. Information needs for a future schedule change
All KIs from all 18 countries stated at least one source of informa-
tion that they perceived would be required for the decision-making
process around a future, hypothetical HPV vaccine schedule change
(Table 4). Often multiple sources of information were listed.
KIs from nine countries thought that a WHO position paper or a
WHO recommendation would be required before policy makers would
consider a change to a one dose HPV schedule. Only KIs from Argentina
stated explicitly that policy makers would not necessarily wait for
formal WHO recommendations to enact a change in vaccination policy
(e.g. schedule changes), unless there was significant controversy around
the decision. KIs from eight countries (Argentina, Brazil, Lesotho, Peru,
Senegal, Uganda, Country Z and Zambia) stated that evidence on the
efficacy of one dose of HPV vaccine against HPV infection and/or
clinical endpoints compared to two or three doses would be important
in the decision-making process around recommending a change in
schedule. KIs from 10 countries (Lesotho, Country Z, Nigeria, Senegal,
Nepal, Argentina, Bolivia, Brazil, Colombia and Moldova) mentioned
that evidence on the immunogenicity of one dose of HPV vaccine
Table 2
Perceived advantages of a single dose HPV vaccine schedule.
Perceived advantages of a 1-dose schedule KIs N=30a Countries N=18
Reduction in HPV vaccine programme costs 15 11
Operational/logistical advantagesb 15 12
High coverage of one dosec 7 7
Easy integration into routine immunisation services/ other services e.g. annual child health days 7 6
Lower cold chain requirements 3 2
Increased community acceptability due to fewer visits/ injections 3 3
Potential to extend HPV vaccination to a wider cohort or boys or older women given the reduced cost of a one dose scheduled 2 2
Did not want to respond 3 3
a KIs cited more than one advantage.
b Operational or logistical advantages referred to easier implementation of one dose in schools including less interruption of school activities, fewer visits and ease
of integration into routine immunisation services or existing outreach services.
c Seven representatives from seven countries reported high first dose coverage in previous HPV vaccine programmes but lower second dose coverage and would
therefore welcome the opportunity to be able to report the higher first dose coverage as overall coverage.
d Brazil and Bolivian representatives mentioned the savings from a single dose programme could be reinvested to widen the target group for HPV vaccine.
Table 3
Perceived barriers to 1 dose HPV vaccine schedule.
Perceived barriers to 1 dose HPV vaccine
schedule
KIs N=30a Countries N=18
No barriers perceived 14 13
Community or individual acceptanceb 8 6
Acceptability among healthcare workers 6 6
Negative media or anti-vaccine groups 3 3
Cost of re-mobilisation/ retraining necessary 5 5
Did not respond/ did not want to hypothesize 2 2
a KIs cited more than one barrier.
b Community or individual acceptance refers to communities questioning
whether one-dose is sufficient, or concerns raised over whether 2/3 doses were
therefore too much.
Table 4
Countries classified by the highest level of evidence that KIs perceived may be needed for any future discussions on a further reduction of the HPV vaccine schedule.
Reported evidence needed for
consideration
Immunogenicity data Efficacy data against a clinical endpoint (+/-
immunogenicity data)
WHO position paper (+/- efficacy +/-
immunogenicity data)
Countries Nigeria Lesotho Ethiopia
Colombia Country ‘Z’ Senegal
Moldova Argentina Uganda
Brazil Laos
Zambia Nepal
Zimbabwe Solomon Islands
Bolivia
Peru
Kenya
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compared to two or three doses would be important for the decision-
making process.
3.4. Perceived implications of a schedule change on HPV vaccine delivery
strategy and the affordability
KIs from all 18 countries discussed the perceived implications of a
schedule change on the vaccine delivery strategy. The majority of KIs
stated that a change in schedule would not alter the recommended
delivery strategy for HPV vaccine in their country (Table 5). KIs from
just two countries (Country Z and Zambia) mentioned that a single dose
strategy may be easier to integrate with existing annual health day
campaigns rather than delivery through their routine existing health
system activities and therefore a change of delivery strategy may be
considered.
KIs from 15 countries offered their opinions on affordability and KIs
from the same country were in agreement on this point. Four KIs from 3
countries were unsure as to what extent the reduction of schedule
would affect the cost of the HPV vaccination programme. The re-
maining 18 KIs from 12 countries (Argentina, Bolivia, Brazil, Ethiopia,
Kenya, Lao, Lesotho, Moldova, Country Z, Nepal, Zambia, Zimbabwe)
perceived that a reduction in schedule would reduce the overall cost of
vaccine procurement and delivery. Lesotho mentioned that a reduction
in schedule and concomitant reduction in programme cost could help
re-start the national HPV vaccination programme. The KI from Moldova
stressed that despite a potential reduction in cost, political will would
need to increase for the HPV vaccine to be successfully introduced
nationally:
“There is not sufficient political support at this moment… Currently the
National Immunization Program is entirely covered from the State budget
and HPV vaccine is the most expensive one out of the whole spectrum of
vaccines proposed for funding by the Immunization Program” KI
Moldova
Despite recognising that a reduced schedule could potentially sub-
stantially reduce the cost of the HPV vaccine programme, KIs from 7
countries (Ethiopia, Lao, Country Z, Nepal, Solomon Islands, Uganda,
Zimbabwe) mentioned residual concerns over the sustainability of their
HPV vaccine programme:
“It is already hard to sustain the vaccines that we have in our pro-
gramme. Introducing a new one is increasing the burden that we already
have. But of course… the one dose approach would be much, much easier
to manage.” KI Country Z
Two KIs (Ethiopia, Zimbabwe) specifically stated that for the pro-
grammes to be sustainable, the cost of the vaccine still needs to reduce,
despite a one dose schedule and Gavi support.
“[One dose] will help in the shorter-term… HPV will only be sustained
longer-term if the price of that 1 dose is negotiated again” KI Ethiopia
“The price of the vaccine still needs to be reduced even with a reduction
to one dose.” KI Zimbabwe
Among the 12 countries eligible for Gavi support, 8 KIs in 6 coun-
tries mentioned the approaching transition away from Gavi support as a
contributing factor to their assessment of the implications of a one dose
schedule on cost and sustainability of the HPV programme:
Table 5
HPV vaccine delivery experience and perceived implications of a further schedule change to the vaccine delivery strategy.
Country HPV vaccine
experience
Delivery strategy experience KI perspective on potential changes to delivery strategy if 1 dose schedule was
implemented
Ethiopia Gavi demo 2015–17 Demo exp: School based + community
outreach
No change
Natl. plans: School based
Kenya GAP demo 2011; Natl. plans: School based No change but would propose to integrate with another service delivered in schools such
as deworming or health education on hygiene i.e the school health days or malezi bora
campaigns
Gavi demo 2013–17
Lesotho GAP demo(s)
2009–2011;
Natl. exp: School-based Integrate into routine immunisations services at the health facility with outreach
National 2012-
Country ‘Z′ Gavi demo 2014–15 Demo exp: School + health centre based
+ outreach
Uncertain; potentially integrated with annual vitamin A campaigns
Nigeria None N/A Uncertain
Senegal Gavi demo 2015–17 Demo exp/ Natl. plans: School + health
centre based +outreach
No change
Uganda Demo(s) 2008–14 Natl. exp: health facility based +outreach No change
Natl. 2015-
Zambia GAP demo 2013–14 Demo exp: Schools +health facilities Potentially integrate into Child Health Week campaign, which includes deworming and
immunisation
Zimbabwe Gavi demo 2015–17 Demo exp: School + health centre based
+ outreach.
No change
Natl. plans: School + health facility
Lao PDR Gavi demo 2013–15 Demo exp: School + health centre based
+ outreach.
Unknown
Nepal Demo 2008–2015 Demo exp: School + health centre based No change
Solomon Islands Gavi demos 2015–17 Demo exp: School + health centre based
+ outreach.
No change; easier to integrate with TT and Oral Polio vaccine outreach delivered by the
school health programme
Argentina Natl: 2011- Natl. exp: school +Health facility
+ outreach (dependent on province)
No change; currently integration of Hepatitis B, rubella, meningitis and first dose of HPV
Bolivia Demos 2009–2011 School based No change; possibly integrate with tetanus
Natl: 2017-
Brazil Demos 2010–12 Natl. exp: school +Health facility No change. Integrated with Meningitis C and diphtheria vaccine
Natl. 2014-
Colombia Natl. 2012- Health centres No change
Peru Demos 2007–2010 Natl. Exp: School based No change
Natl. 2011-
Moldova Gap Demo 2010–11 Demo. Exp: School-based Uncertain
Abbreviations: Demo: Demonstration project; exp: experience; Natl: National programme. Information collated from KIs and Gavi application documents at gavi.org.
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“Current national rollout support from Gavi ends in 2021. The country is
going to take on board [the cost of] not just HPV vaccine, but other
vaccines as well… The executives are aware of our transition, that we are
graduating soon from Gavi, so they are working out whether other sup-
port will come once we have graduated from Gavi.” KI Solomon Islands
KIs from Kenya and Uganda specifically stated that a single dose
programme could alleviate costs and resources associated with tracing
and catch-up of girls who miss their second/third dose.
3.5. Views on off-label vaccine use
KIs from nine of the 18 countries interviewed knew of no prior
experience of off-label vaccine use in their country (Table 6). KIs from
four countries reported that policy makers were currently considering
off-label vaccination with the delivery of fractional doses of inactivated
polio vaccine (IPV). KIs from all five of the Latin American countries
interviewed reported that their countries had had previous experience
of national introduction of vaccines off-label without/prior to WHO
recommendations e.g. the use of a single dose schedule of Hepatitis A
vaccine (Argentina, Brazil), a single dose schedule of varicella vaccine
(Argentina), early introduction of a reduced schedule of three doses of
pneumococcal conjugate vaccine (Argentina, Peru), fractional dose IPV
(Colombia), prolonged storage of IPV (Bolivia) and administration of a
pertussis vaccine in pregnancy (Argentina, Colombia).
4. Discussion
Key immunisation stakeholders from 27 countries were approached
for interview; thirty key informants from 18 countries (67%) provided
written consent to be interviewed. Overall, the KIs interviewed
suggested there would be support for a hypothetical future simplifica-
tion of the HPV vaccine schedule to a single dose. It was generally
acknowledged that this would reduce the resources required for de-
livery, the discomfort and inconvenience to the vaccinees and the fi-
nancial commitment required for vaccine procurement. A number of
KIs stressed that, although a single dose schedule might alleviate some
of the logistical and financial challenges of HPV vaccine delivery, there
remained a need for strong political will, social mobilisation and
healthcare worker training to ensure programme success and longevity.
Some KIs also called for continued efforts to reduce the vaccine per-
dose cost, citing residual concerns over HPV vaccine programme sus-
tainability. Due to these remaining concerns over the sustainability of
even a single-dose programme, only two respondents saw the reduction
in schedule as an opportunity to expand coverage to other target
groups.
The decision-making processes and information needs for a future
hypothetical one dose schedule change were fairly similar across
countries. WHO recommendations on vaccine introduction and delivery
play an important role, especially in Africa, in decisions to introduce or
change vaccine programmes. WHO recommendations are also used to
reassure communities about a change in vaccine policy should negative
media or rumours arise. KIs from half the countries interviewed stated
that they felt a WHO recommendation for a single dose schedule would
be needed prior to a schedule change in their country, whereas others
were uncertain on this point. KIs from three of the 18 countries speci-
fically stated that they would want to hear lessons from other countries
that had introduced a single dose schedule i.e. that they would not want
to be the first to implement. There were concerns that the change in
policy could fuel negative media coverage of the national immunisation
programme.
Known prior experience of off-label vaccine use was concentrated in
Table 6
Summary of key findings by country.
Date of
national HPV
vaccine intro’
Readiness and perceived advantages Barriers Information needs
Country Would
support 1-
dose
NITAG in place Experience of off-
label vaccine use
Community
mobilisation
neededa
HCW
mobilisation
neededb
Concerns
over negative
media
WHO
recommendation
required
Other
country
lessons on 1-
dose
Ethiopia 2018f Yes Yes No Yes Yes Yes Yes
Kenya 2019f Yes Yes No Yes Yes Yes Yes
Lesotho 2012–16 Yes None (in
development)
Under
consideration
Country Z NA Yes Yes No
Nigeria NA Yes Yes No
Senegal 2018f Yes Yes No Yes Yes
Uganda 2015- Yes Yes No Yes Yes
Zambia 2019f Yes Yes Under
consideration
Yes Yes
Zimbabwe 2018f Yes Yes Noc Yes Yes
Lao PDR 2019f Yes Yes Noc Yes Yes Yes
Nepal NA Yes Yes Under
consideration
Yes
Solomon
Islands
2019f Yes None Yes (current) Yes
Argentina 2011- Yes Yes Yes (past) Nod
Bolivia 2017- Yes Yes Yes (past) Yese
Brazil 2014- Yes Yes Yes (past)
Colombia 2012- Yes Yes Yes (past) Yes Yes Yes
Peru 2011- Yes Yes Yes (past) Yes Yes
Moldova NA Yes Yes No
a Concerns were raised over community acceptance of (another) schedule change/ mistrust/ the additional resources needed to re-mobilise the community.
b Concerns over health care worker acceptance of a new schedule and the additional resources needed for re-training.
c KIs indicated any approval for off-label use would take a long time to be processed and/or would not be considered.
d KIs in Argentina were the only KIs to indicate that WHO recommendation would not necessarily be needed prior to introduction of a change in HPV schedule
(other KIs either explicitly stated they would be needed or did not mention them).
e Bolivian KIs also mentioned manufacturer recommendations for the schedule change may be needed.
f Projected introduction date based on Gavi application; NA: unknown/ not available.
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the South American countries that were interviewed. There may be
other examples of off-label vaccine use that were not reported by the
KIs. There were a number of limitations with the study; we were not
able to collect information from nine of the 27 countries approached for
interview and the interviews conducted represented the individual
opinions of the KIs rather than a consensus reached by those making of
advising vaccination policy. There may be different conclusions drawn
e.g. on the information needed prior to a schedule reduction or the
implications of a schedule change on the recommended delivery
strategy, if the decision-making processes in the country were followed
and relevant committees and advisory groups consulted.
5. Conclusions
In conclusion, we found wide ranging support among 27 im-
munisation programme stakeholders from 18 LMICs for a future further
reduction in the HPV vaccine schedule to a single dose, if there is im-
munological and clinical evidence of efficacy. Randomised controlled
trials are underway to analyse whether a single dose of HPV vaccine
delivers non-inferior immunogenicity and efficacy compared to 2 and 3
dose regimens.
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